Gracell Biotechnologies Inc (DELISTED) (GRCL:DL)
10.25
0.00 (0.00%)
USD |
NASDAQ |
Feb 22, 16:00
Gracell Biotechnologies SG&A Expense (Quarterly): 4.381M for Sept. 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 4.381M |
| June 30, 2023 | 5.329M |
| March 31, 2023 | 4.250M |
| December 31, 2022 | 5.086M |
| September 30, 2022 | 5.319M |
| June 30, 2022 | 4.352M |
| March 31, 2022 | 5.961M |
| December 31, 2021 | 5.000M |
| Date | Value |
|---|---|
| September 30, 2021 | 6.618M |
| June 30, 2021 | 4.709M |
| March 31, 2021 | 4.895M |
| December 31, 2020 | 3.738M |
| September 30, 2020 | 1.182M |
| June 30, 2020 | 0.9832M |
| March 31, 2020 | 0.8057M |
| December 31, 2019 | 1.125M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.8057M
Minimum
Mar 2020
6.618M
Maximum
Sep 2021
3.983M
Average
4.545M
Median
SG&A Expense (Quarterly) Benchmarks
| RayzeBio inc (DELISTED) | 3.481M |
| Zai Lab Ltd | 82.63M |
| WuXi Biologics (Cayman) Inc | -- |
| Axonics Inc | 71.30M |
| I-MAB | -- |